Personalized cancer vaccine in killer combo with immunotherapy

Personalized cancer vaccine RO7198457 and immunotherapy drug atezolizumab work cohesively to induce tumor-specific immune responses in 73% of patients. Patients with advanced solid tumors have clinically benefited from treatment with a personalized cancer vaccine in combination with the immunotherapy drug atezolizumab, according to results presented at the AACR Virtual Annual Meeting II (22–24 June 2020). “Many cancers are able to successfully avoid the immune system, and we are only starting to understand the myriad ways in which cancers can do this,” explained lead researcher Juanita Lopez (The Institute of Cancer Research, London, UK). “Because many mutations are not shared between...